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Fungal pathogens have a robust array of multidrug transporters which aid in active
expulsion of drugs and xenobiotics to help them evade toxic effects of drugs. Thus,
these transporters impose a major impediment to effective chemotherapy. Although
the Saccharomyces cerevisiae strain AD1-8u− has catered well to the need of an
overexpression system to study drug transport by multidrug transporters of Candida
albicans, artifacts associated with a heterologous system could not be excluded.
To avoid the issue, we exploited a azole-resistant clinical isolate of C. albicans to
develop a new system devoid of three major multidrug transporters (Cdr1p, Cdr2p,
and Mdr1p) for the overexpression of multidrug transporters under native hyperactive
CDR1 promoter due to gain of function (GOF) mutation in TAC1. The study deals with
overexpression and functional characterization of representatives of two major classes
of multidrug transporters, Cdr1p and Mdr1p, to prove the functionality of this newly
developed endogenous expression system. Expression of native Cdr1 and Mdr1 protein
in C. albicans cells was confirmed by confocal microscopy and immunodetection and
resulted in increased resistance to the putative substrates as compared to control. The
system was further validated by overexpressing a few key mutant variants of Cdr1p and
Mdr1p. Together, our data confirms the utility of new endogenous overexpression system
which is devoid of artifactual factors as most suited for functional characterization of
multidrug transporter proteins of C. albicans.
Keywords: Candida albicans, multidrug transporters, endogenous overexpression system, Cdr1p, Mdr1p, TAC1
GOF
INTRODUCTION
C. albicans, an otherwise commensal of the human microbiome, can become causative agent of
superficial as well as life-threatening systemic infections (Staib et al., 2000). Prolonged use of
antifungals, primarily azoles, has led to the emergence of Multidrug resistance (MDR). Although
MDR is a multi-factorial response, the overexpression of membrane pumps such as ABC (ATP-
binding Cassette transporters) andMFS (Major-Facilitator Superfamily) transporters are the prime
actors in contributing to the development of tolerance to drugs (White, 1997; Rogers and Barker,
2003).
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Heterologous overexpression of MDR pump proteins of
C. albicans in Saccharomyces cerevisiae has been widely used
as a novel tool for the structure-function analyses of these
transporters. Such studies unpinned crucial molecular details
of drug eﬄux, protein trafficking and transport cycle (Lamping
et al., 2007; Pasrija et al., 2007; Rawal et al., 2013; Shah et al.,
2015a,b). Furthermore, this system also provided novel insights
regarding array of substrates recognized by these transporters
(Puri et al., 2010) and critical amino acids involved in the
substrate and inhibitor recognition (Saini et al., 2005; Pasrija
et al., 2007; Niimi et al., 2012; Rawal et al., 2013; Nim et al., 2014).
Together, the afore-mentioned applications of the heterologous
system has helped in the development of therapeutic inhibitors
and modulators of eﬄux pumps (Hayama et al., 2012; Maurya
et al., 2013).
In spite of their insightful contributions, artifactual concerns
associated with a heterologous background could not be
neglected. Differences pertaining to the membrane components,
primarily lipids could influence the insertion and proper
association of the foreign transporters within the membrane
compartment and thus might have an impact on the structural
as well as functional properties of these proteins (Opekarova
and Tanner, 2003). Moreover, the alternative codon usage of
C. albicans requires mutational corrections of some codons when
specific C. albicans genes need to be expressed in S. cerevisiae
(Santos and Tuite, 1995).
To circumvent artifactual effects of a heterologous system and
also to avoid the need of codon corrections, we have developed
here an endogenous model system for the overexpression of
clinically relevant multidrug transporters of C. albicans. For
this, we used an azole-resistant clinical isolate of C. albicans
where genes encoding major drug transporters CDR1, CDR2,
and MDR1 were deleted. This strain, although deleted of its
major MDR attributes, still contains a gain of function (GOF)
mutation in TAC1 transcription factor which is responsible for a
constitutive overexpression of CDR1 (Znaidi et al., 2007). A GFP
tagged variant of Cdr1p was generated and integrated at its native
chromosomal locus. It was observed that the overexpressed
protein was properly localized to the plasma membrane and
could confer drug resistance to the strain. The study confirms that
this overexpression system is not only suitable for the expression
ofCDR1 but equally suitable for non-ABC transporter genes such
asMDR1.
MATERIALS AND METHODS
Bacterial and Yeast Strains
Yeast strains used in the study are listed in Table 1. Plasmids
were maintained in E. coli Dh5α strain cultured in Leuria
Bertani medium (HiMedia Laboratories, Mumbai, India) to
which ampicillin (Amresco, Solon, USA) was added at a final
concentration of 0.1 mg/ml. The yeast strains were cultured
in either YEPD broth or on YEPD agar plates. YEPD broth
was procured from HiMedia Laboratories, Mumbai, India. For
selection of yeast transformants after integration, SD-Ura− drop
out medium with 2% agar was used. SD-Ura− drop out medium
comprised of 0.67% YNB medium without amino acids (Difco,
TABLE 1 | List of yeast strains used in the study.
Strain Genotype/Description Parent strain Source/
Reference
STY31 cdr2A1::FRT/cdr2B1::FRT
cdr1A1::FRT/cdr1B1::FRT
5674 Tsao et al.,
2009
DSY4680 cdr2A1::FRT/cdr2B1::FRT
cdr1A1::FRT/cdr1B1::FRT
ura31::FRT/ura31::FRT
STY31 This study
DSY4684 cdr2A1::FRT/cdr2B1::FRT
cdr1A1::FRT/cdr1B1::FRT
ura31::FRT/ura31::FRT
mdr11::hisG/mdr11::hisG
DSY4680 This study
DSY4687-5 cdr2A1::FRT/cdr2B1::FRT
cdr1A1::FRT::CDR1-
GFP::URA3 /cdr1B1::FRT
ura31::FRT/ura31::FRT
mdr11::hisG/mdr11::hisG
DSY4684 This study
ANY-L529A cdr2A1::FRT/cdr2B1::FRT
cdr1A1::FRT::CDR1L529A
-GFP::URA3 /
cdr1B1::FRT
ura31::FRT/ura31::FRT/
mdr11::hisG/
mdr11::hisG
DSY4687-5 This study
ANY-V532A cdr2A1::FRT/cdr2B1::FRT
cdr1A1::FRT::CDR1V532A
-GFP::URA3 /
cdr1B1::FRT
ura31::FRT/ura31::FRT/
mdr11::hisG/
mdr11::hisG
DSY4687-5 This study
ANY-C1294A cdr2A1::FRT/cdr2B1::FRT
cdr1A1::FRT::CDR1C1294A
-GFP::URA3 /
cdr1B1::FRT
ura31::FRT/ura31::FRT/
mdr11::hisG/
mdr11::hisG
DSY4687-5 This study
ANY-MDR1-GFP cdr2A1::FRT/cdr2B1::FRT
cdr1A1::FRT::MDR1-
GFP::URA3)/cdr1B1::FRT
ura31::FRT/ura31::FRT
mdr11::hisG/mdr11::hisG
DSY4684 This study
ANY-W248A cdr2A1::FRT/cdr2B1::FRT
cdr1A1::FRT::MDR1W248A–
GFP::URA3 /cdr1B1::FRT
ura31::FRT/ura31::FRT
mdr11::hisG/mdr11::hisG
ANY-MDR1-GFP This study
Detroit, MI), 0.2% Ura− dropout mix and 2% glucose (Fisher-
Scientific, Mumbai, India).
Materials
Itraconazole (ITC), Clotrimazole (CTR), Ketoconazole (KTZ),
Miconazole (MCZ) and Voriconazole (VOR), Anisomycin
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(ANI), Rhodamine 6G (R6G), 4-nitroquinoline 1-oxide
(NQO), Adenosine triphosphate (ATP), Oligomycin (OM),
DL-Dithiothreitol (DTT), Sorbitol, Phenylmethanesulfonyl
fluoride (PMSF), p-Tosyl-L-lysine chloromethyl ketone (TLCK),
and Tosyl phenylalanyl chloromethyl ketone (TPCK) were
procured from Sigma Chemical Co. (St. Louis, MO). Protease
inhibitors leupeptin, aprotinin, Pepstatin were obtained from
G-biosciences, MO, USA). Fluconazole (FLC) was a generous
gift from Ranbaxy Laboratories, India. Oligonucleotides were
procured from Sigma Genosys, India and are listed in Table S2.
Anti-GFP monoclonal antibody was purchased from Santa Cruz
Biotechnology Inc. (Texas, USA). All other routine chemicals
were purchased from Fisher-scientific, Mumbai, India.
Plasmid Constructions
The homologous expression system was constructed based on
Clp10 (Murad et al., 2000). The CDR1 terminator (CDR1ter)
(starting 21 nt downstream of the CDR1 stop codon) was first
cloned as a 519 bp NotI-SacI fragment into Clp10 to obtain
pDS1859 (Table S1). The NotI-SacI fragment CDR1ter was
obtained by PCR using C. albicans SC5314 DNA as template
with primers CDR1ter_SacI and CDR1Ter_NotI. Next, pDS1859
was used to insert a modified CDR1 promoter (−1222 bp with
respect to first ATG codon) in which a natural SpeI site was
destroyed. This was accomplished by a two-step fusion PCR using
a first fragment obtained with primers CDR1-Apa and SpeKO3
and a second fragment obtained with primers CDR1-SpeI and
SpeKO5. The two purified PCR fragments were sewed by PCR
using external primers CDR1-Apa and CDR1-SpeI. The obtained
fragment was cloned in pDS1859 using ApaI and SpeI restriction
sites to result in pDS1866. Next, the S. cerevisiae PDR5 terminator
was inserted as a SpeI-NheI fragment from pPSCDR1-GFP into
pDS1866 to result in pDS1869. Finally the CDR1-GFP fusion
from pPSCDR1-GFPwas cloned as a SpeI fragment into pDS1869
to result in pDS1874.
For cloning of MDR1-GFP, the MDR1-GFP fusion from
pPSMDR1-GFP was obtained by SpeI digestion. The fragment
was next cloned in pDS1874 to replace CDR1-GFP, thus resulting
in pAN-MDR1. The BglII site present in MDR1 cloned in pAN-
MDR1 was removed by site directed mutagenesis.
Yeast Strain Constructions
The C. albicans strain STY31 (a kind gift from M. Raymond,
Montreal) that lacks CDR1 and CDR2 (Tsao et al., 2009) was used
as a starting strain for the deletion of MDR1. First, URA3 alleles
were inactivated sequentially using pSFSU1 (Coste et al., 2006)
in STY31 to obtain DSY4680 after sequential URA3 inactivation
and recycling of the SAT1 dominant marker. DSY4680 was
used to inactivate both MDR1 alleles with pDS287 as described
(Sanglard et al., 1996). The resulting strain lacking CDR1, CDR2,
and MDR1 was named DSY4684. This strain contains the TAC1
GOF N972D (Znaidi et al., 2007; Tsao et al., 2009). CDR1-GFP
expression could be obtained in this strain by transformation
with pDS1874 digested by BglII to facilitate integration in
the CDR1 promoter. MDR1-GFP expression was obtained in
DSY4684 by transformation with pAN-MDR1 digested by BglII
to facilitate integration in the CDR1 promoter.
Site-Directed Mutagenesis
Site-directedmutagenesis was performed by usingQuick-Change
site directed mutagenesis kit (Agilent Technologies, USA). The
mutations were incorporated in pDS1874 and pAN-MDR1
plasmids according to the manufacturer’s instructions and the
nucleotide changes were confirmed by sequencing. Confirmed
plasmid clones were used for transformation of DSY4684
using electroporation after linearization with BglII as described
previously (Puri et al., 2011).
Drug Susceptibility Assays
The susceptibilities of the different yeast strains to different drugs
were tested using broth microdilution and serial dilution spot
assays as described previously (Shah et al., 2015b).
Agar Drug Diffusion Assay
Overnight grown cultures were diluted to an OD600 of 0.01
in YEPD agar and poured onto petri plate. Whatman paper
filter discs containing the xenobiotics were placed on top of the
YEPD agar plate and incubated for 48 h at 30◦C. Amount of
xenobiotics used are mentioned in the figure legends. For the
chemosensitization assay, FLC at 1/4 MICFLC was added to the
YEPD agar containing 105 cells and the inhibitor containing disc
was placed on to the plate.
Immunodetection of GFP Tagged Proteins
Plasma membrane fractions used for immunodetection of GFP
tagged proteins were prepared as described previously (Shukla
et al., 2003) with minor modifications. Here, cells used for
preparation for PM fractions were harvested after 8 h of
growth. 50 micrograms of total PM proteins were used for
immunodetection with HRP-labeled anti-GFP antibody at 1:5000
dilution. Protein bands were detected by BIO-RAD ChemiDoc
XRS+ system following reaction with Clarity Western ECL
blotting substrate (Bio-Rad).
Immunodetection of Cdr1
C. albicans total protein extracts were prepared as described
(Coste et al., 2007). Same protein quantites were loaded
for gel eletrophoresis and Cdr1 immunodection was
performed as earlier described by chemiluminescence (ECL
kit, Amersham, Bioscience) using polyclonal rabbit anti-Cdr1
antibody and an anti-rabbit-HRP labeled secondary antibody.
Chemiluminescence was recorded with a ImageQuant LAS 4000
mini CCD camera (GE Healthcare Bio-Sciences).
Fluorescence and Confocal Microscopy
Cells were harvested at the requisite time points from a secondary
culture, washed and viewed under Nickon Ti90 fluorescence
microscope to visualize the GFP-tagged protein. For Confocal
microscopy, 8 h grown cells were harvested and imaged using
Olympus FluoViewTMFV1000 laser confocal microscope (PA,
USA) orNickon Eclipse Ti E laser confocal microscope with 100X
oil immersion objective lens.
Substrate Transport Assays
R6G eﬄux of the strains was determined as described previously
(Shah et al., 2015b) with minor modifications. Briefly, overnight
Frontiers in Microbiology | www.frontiersin.org 3 March 2016 | Volume 7 | Article 261
Banerjee et al. C. albicans MDR Pump Overexpression System
grown cultures were used to set an OD of 0.4 in 15 ml of
YEPD medium. The cultures were then grown for 8 h. Cells were
harvested, washed and resuspended in 1.5 ml Phosphate buffered
saline (PBS) to make a final OD of 10. The cell suspension was
then grown in the presence of R6G at 10 µM final concentration
for 2 h. Cells were then harvested, washed and resuspended
in 1.5 ml PBS containing 2% glucose. After 45min, cells were
pelleted and 1ml of the supernatant was used to measure the
absorbance at 530 nm. For NR accumulation, 8 h grown cultures
were used to set 0.2 OD in 1 ml of PBS containing 2% glucose.
The suspension was incubated with 7 µM final concentration
of NR. After 45 min, the cells were harvested, washed with
PBS and used and NR accumulation was monitored by flow
cytometry using a FACSort flow cytometer (Becton–Dickinson
Immunocytometry Systems, San Jose, CA). CellQuest software
(Becton-Dickinson Immunocytometry Systems, San Jose, CA)
was used for data analysis. For [3H] FLC (specific activity 2.8
Ci/mmol) accumulation assay, log phase cells were harvested,
washed with PBS (Phosphate buffered saline, pH 7.4) and finally
resuspended as 5% cell suspension. After de-energization at 30◦C
for 2 h, 0.25 ml of 5% cell suspension (in PBS with 2% glucose)
was incubated with 100 nM final concentration of [3H] FLC.
A 100 µl aliquot was taken after 60 min of incubation at 30◦C
filtered through a 0.45µm cellulose nitrate filter using millipore
manifold filtration assembly and washed twice with PBS. The
filter discs were dried under a lamp and then immersed in liquid
scintillation cocktail mixture (Cocktail O, SRL, India) to measure
the accumulated radioactivity using liquid scintillation counter
(Tri-Carb 2900TR Liquid Scintillation Analyzer; Packard).
Oligomycin-Sensitive ATPase Assay
ATPase activity of the strains was monitored by the oligomycin-
sensitive release of inorganic phosphate as described previously
(Shah et al., 2015b). Briefly, 10µg total PM protein was used
to determine the ATPase activity in an in vitro assay. 5mM
ATP was used in the reaction mixture which was terminated
after 30min of incubation at 30◦C by addition of 1ml of stop
solution which contained 0.5% SDS, 0.5% ammoniummolybdate
and 2% H2SO4. 10 µl of 10% ascorbic acid was added to the
solution and further incubated for 30 min for development of
color. Absorbance of the solution was measured at 880 nm to
assess the Pi release.
Statistical Analyses
Data is represented as mean ± SD. The statistical analyses were
performed using Student’s T-Test (http://www.studentsttest.
FIGURE 1 | (A) Schematic representation of the C. albicans transporter overexpression system. The system contains the promoter and terminator regions of CDR1
and a URA3 selection marker. The SpeI cloning site in the plasmid can be used to insert the gene of interest. A S. cerevisiae PDR5 terminator is situated downstream
of the SpeI site. The plasmid can be linearized by BglII digestion and integrated into the host strain DSY4684 which is devoid of three major MDR pumps of
C. albicans (CDR1, CDR2, and MDR1). The host strain also has a GOF mutation in the TAC1 transcription factor as a result of which the cloned ORF is overexpressed
under the native CDR1 promoter. (B) Time course fluorescence microscopy of DSY4687-5 strain (overexpressing Cdr1-GFP) grown in YEPD and YNB medium. Lower
panel shows growth curve of the strain in the two mentioned medium at the time points used for microscopic analyses.
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com/). Differences were considered statistically significant when
p< 0.05 (∗ signifies p< 0.05, ∗∗ signifies p≤ 0.01 and ∗∗∗ signifies
p ≤ 0.001).
RESULTS
Expression of Cdr1-GFP in a MDR
Depleted Strain of C. albicans
An AR isolate with a GOF mutation in TAC1 was further
derivatized by deleting its major MDR pump candidates, Cdr1p,
Cdr2p, and Mdr1p as well as URA3 for selection. This strain
was designated as DSY4684. The CDR1 gene with a C-terminal
GFP tag was introduced at the native chromosomal locus in
DSY4684 by homologous recombination using URA3 as the
selection marker. The integration of the CDR1-GFP chimeric
construct was performed by single (BglII) digestion of pDS1874.
Resulting strain was designated as DSY4687-5 (Figure 1A)
and (Figure S1). Fluorescence microscopy at different growth
time points revealed that Cdr1-GFP was overexpressed and
correctly trafficked to the plasma membrane (PM) of DSY4687-5
(Figure 1B). Notably, the fluorescent intensity of Cdr1-GFP was
the highest at 4 hours of growth and declined subsequently with
time. A significant amount of fluorescence was observed within
the vacuoles after 12 hours indicating that the overexpressed
protein was being targeted to the vacuole for degradation. This
expression trend was common in both defined (YNB) and
enriched medium (YEPD). At 8 hours of growth, a considerable
amount of the protein was still visible within the PM which
was confirmed by confocal and immunoblot analyses of the
PM fractions with an anti-GFP antibody (Figure 2A). Since
the cellular yields were sufficient for functional analyses, all
the subsequent studies were performed at this growth time
point.
Overexpressed Cdr1-GFP is Functional
We evaluated the drug susceptibilities of DSY4687-5 and
DSY4684 strains to assess the substrate transport ability of
the overexpressed Cdr1-GFP. MIC80 values for the above
mentioned strains against the four well known Cdr1p substrates
including Fluconazole (FLC), Ketoconazole (KTZ), Miconazole
(MCZ), and Rhodamine 6G (R6G) confirmed that these
drugs were efficiently eﬄuxed by the overexpressed protein
(Figure 2B). Interestingly, overexpression of Cdr1p increased
the resistance of DSY4684 to FLC and MCZ by more than
50- and 100-fold, respectively, whereas the fold change in
resistance to KTZ and R6G was 30 and 2-fold, respectively.
Agar drug-diffusion assays were employed to validate
MIC80 results, which also confirmed the functionality of
overexpressed Cdr1-GFP in DSY4684. It was evident from
the difference in zone-of-inhibition between the tested strains
FIGURE 2 | (A) Confocal microscopy images of DSY4684 and DSY4687-5 strains (Upper panel) and immunoblot analyses of the PM fractions (50 µg total protein)
with anti-GFP monoclonal antibody (Lower panel). (B) MIC80 values of DSY4684 and DSY4687-5 cells for Fluconzole (FLC), Ketoconazole (KTZ), Miconazole (MCZ)
and Rhodamine 6G (R6G). (C) Agar drug-diffusion assays of DSY4684 and DSY4687-5 cells. Susceptibility to the following azoles were tested: Fluconazole (FLC; 10
µg), Itraconazole (ITC; 1 µg), Clotrimazole (CTR; 0.5 µg), Ketoconazole (KTZ; 0.2 µg), Miconazole (MCZ; 0.2 µg) and Voriconazole (VOR; 1 µg).
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that Cdr1-GFP could recognize and eﬄux its substrates
(Figure 2C).
Phenotypic Analysis of Selected Mutants
of Overexpressed Cdr1p in C. albicans
In order to further validate the newly designed endogenous
expression system, we subjected the Cdr1-GFP to site directed
mutational analyses. For this, we selected three residues, L529,
V532, and C1294 which were earlier shown to be crucial
for the eﬄux of substrates of Cdr1p (Rawal et al., 2013).
All the three mutant variants (L529A, V532A, and C1294A)
overexpressed in S. cerevisiae rendered cells hypersusceptible to
all the tested drugs. Substrate binding/transport and molecular
modeling predicted that the three residues including L529,
V532, and C1294 are part of the drug binding pocket (Rawal
et al., 2013). Figure 3A highlights the positions of these residues
within the transmembrane helices (TMHs). For instance, L529
and V532 are part of the TMH1 whereas C1294 is located
within TMH9. Considering their importance, we recreated the
alanine variants of these critical residues (L529A, V532A, and
C1294A) and integrated them to native chromosomal location
in DSY4684. The resulting strains were designated as ANY-
L529A, ANY-V532A, and ANY-C1294A, respectively. Confocal
microscopy and immunoblot analyses of the PM fractions with
an anti-GFP antibody confirmed that all the mutant variants
of Cdr1-GFP were targeted to the cell surface. However, the
Cdr1V532A variant was expressed at lower levels when compared
to the wild type Cdr1 (DSY4687-5) and the other two variants
(Figures 3B,C).
Serial dilution and liquid drug susceptibility assays were
performed to assess the ability of the mutant variants to confer
drug resistance. Expectedly, the results confirmed that the strains
ANY-L529A and ANY-V532A were hypersusceptible to all the
tested drugs corresponding to the results earlier observed in the
overexpressing S. cerevisiae strain AD1-8u−. Interestingly, the
Cdr1C1294A variant showed only marginal susceptibility to R6G
and remained resistant to other tested drugs (Figures 4A,B).
R6G eﬄux, Nile red (NR) and [3H] FLC accumulation assays
were performed with the WT and the constructed mutant
variants to assess whether the enhanced drug susceptibility of the
mutants coincided with the defect in substrate transport. Flow
cytometry which was employed to measure the NR accumulation
revealed lower accumulation of the fluorescent substrate in WT
cells when compared to DSY4684. All three mutant strains, ANY-
L529A, ANY-V532A, and ANY-C1294A, which were susceptible
to drug(s), displayed intermediate levels of accumulation of NR
(Figure 5A). R6G, another well-known fluorescent substrate of
Cdr1p, was also used to monitor the eﬄux potential of the
mutant variants. In accordance with the susceptibility profile
for R6G, all the mutants showed a defect in transport of this
fluorescent substrate (Figure 5B). The [3H] FLC accumulation
assay corroborated the susceptibility profile of the mutants on
FLC. While ANY-L529A, ANY-V532A showed a statistically
significant defect in FLC transport, ANY-C1294A transport
profile was unchanged as compared to WT. Together, the
FIGURE 3 | (A) Schematic diagram of the topology of Cdr1p with highlighted amino acids selected for replacement by alanine. (B) Confocal analyses of DSY4687-5
and the three constructed mutant variant strains, ANY-L529A, ANY-V532A, and ANY-C1294A. (C) Western analyses of the PM fractions (50 µg total protein) of the
strains with anti-GFP monoclonal antibody.
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FIGURE 4 | (A) Drug resistance profiles of DSY4684, DSY4687-5 and the mutant variants determined by serial dilution spot assays. For the assay, following drugs
were used: FLC (8 µg/ml), KTZ (0.04 µg/ml), MCZ (0.04 µg/ml), R6G (8 µg/ml). (B) MIC80 values of DSY4687-5 and its mutant variants for FLC, KTC, MCZ, and R6G.
transport assays suggested that defect in the transport abilities
of mutant variants of Cdr1p coincided with their antifungal
susceptibilities. In spite of the fact that C1294A mutant was
only partially resistant to R6G, it displayed decreased transport
similar to that of the other twomutants. The oligomycin sensitive
ATPase activity of the PM fractions of WT and mutant strains
were checked to address whether the introduced mutations could
affect the ATP catalysis cycle that could also impact substrates
accumulation levels. Although ANY-L529A and ANY-V532A
had statistically significant lower ATPase activities, this decrease
(both strains retained over 65% activity of WT levels, Figure 6) is
not considered as significant for altering substrate transport. This
is also supported by the case of the ANY-C1294A variant which
retained resistance to azoles and was only partially susceptible
to R6G, even if exhibiting low ATPase activity (50% activity
as compared to WT, Figure 6). Thus, any major role of low
ATPase activity for the observed phenotypes could be excluded.
Of note, the extensive kinetic analysis has revealed that the
three investigated Cdr1p mutants were defective in substrate
binding and not in ATP binding and catalysis when expressed
in S. cerevisiae (Rawal et al., 2013).
FK520 Chemosensitizes Cdr1p
Overexpressing C. albicans Cells to
Fluconazole
We tested the ability of a calceneurin inhibitor FK520 to
chemosensitize DSY4687-5 cells to FLC. Agar drug diffusion
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FIGURE 5 | Substrate transport assays of DSY4684, DSY4687-5 and the mutants. (A) NR accumulation in cells overexpressing Cdr1-GFP and the mutant
variants as determined by Flow cytometry analyses using FL3 filter (B) R6G efflux in cells overexpressing Cdr1-GFP and the mutant variants. Assay was performed as
described in the experimental section. The host DSY4684 values were subtracted from each reading. (C) [3H] FLC accumulation in cells overexpressing Cdr1-GFP
and the mutant variants with respect to DSY4684 (value kept at 100%). *p < 0.05; **p ≤ 0.01.
assay was utilized for this particular investigation. In order to
exclude any growth interference as a result of toxic effects of
the inhibitor itself, the assay was also carried out in the absence
of FLC. Despite that there was a minor reduction in growth of
the cells when exposed to only 1/4 MICFLC, it was observed that
FK520 significantly enhanced the growth inhibition potential of
FLC in the Cdr1p overexpressing system (Figure 7).
MFS Transporter Mdr1 Could be
Functionally Expressed in DSY4684
We explored the newly developed overexpression system
for the structure- function analyses of non-ABC membrane
transporters. For this, we cloned the C. albicans MFS multidrug
transporter protein MDR1 with a GFP tag in pDS1874.After
elimination of a BglII site present in MDR1, the expression
plasmid was linearized by BglII and introduced in CDR1
promoter of DSY4684. The resultant strain was designated
ANY-MDR1-GFP. Confocal microscopy and immunoblot
analyses confirmed the proper localization of Mdr1p to the
PM (Figures 8A,B). Agar drug diffusion assay showed that
overexpressed Mdr1-GFP was fully functional and could
transport the three tested drug substrates [FLC, Nitroquinoline-
oxide (NQO) and Anisomycin (ANS)] (Figure 8C). To further
validate functionality, we also introduced a mutation at one
crucial position (W248A) into Mdr1-GFP and overexpressed
this mutant variant in similar background and the resulting
strain was designated as ANY-W248A. Serial dilution assays on
agar medium containing drugs revealed that this W248A mutant
variant was susceptible to all tested drugs, as was observed earlier
when overexpressed in a S. cerevisiae system (Pasrija et al., 2007;
Figure 8D).
DISCUSSION
It is evident from the current literature that membrane eﬄux
pumps pose a major impediment to effective antifungal therapy
(White et al., 1998; Sanglard and Odds, 2002). Under such a
scenario, it is quite imperative to have a thorough understanding
of the structure and function of multidrug transporters. Thus,
one of the foremost requirements is the need of an overexpression
system which could drive constitutive and functional expression
of the drug transporter proteins with minimum artifactual
effects. Such a system is not only expected to facilitate the
functional characterization of these transporters, but would also
provide a platform for screening of their drug susbstrates and
inhibitors/modulators.
During the past several years, S. cerevisiae has been
successfully exploited as an overexpression system which
provided useful insight into the structure-function aspects and
substrate/inhibitor screening of drug transporter proteins of C.
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albicans. Despite such applications of overexpressing system
of S. cerevisiae by several laboratories, concerns were raised
pertaining to the functionality of C. albicans proteins in a
heterologous background. This concern is even more relevant
FIGURE 6 | Oligomycin-sensitive ATPase activity of DSY4687-5 and its
mutant forms monitored by Pi released from the PM fractions of the
strains. Complete method described in the experimental section. Value of the
WT strain (DSY4687-5) was kept at 100%. Background oligomycin-sensitive
ATPase of the host has been subtracted from all the respective values. ATPase
activities for the host (DSY4684) and WT (DSY4687-5) ranged between 15
and 20 nmoles Pi/mg of total PM protein/min and 60–75 nmoles Pi/mg of total
PM protein/min, respectively. **p ≤ 0.01; ***p ≤ 0.001.
if one considers that the homologs of MDR transporters of
C. albicans and S. cerevisiae follow different regulatory circuits
for their expression. Additionally, since all drug eﬄux pumps are
PM localized, the subtle differences in membrane composition
and architecture between the two yeasts could also have crucial
implications in protein insertion, integrity and function. Lipid
environment for instance, impacts drug transport and ATPase
functions of P-glycoprotein (P-gp) (Saeki et al., 1991; Urbatsch
and Senior, 1995; Sharom, 1997). In particular, the phase state
of lipid bilayer is crucial for ATPase activity of P-gp (Sharom,
1997). The membrane component, cholesterol, is also well
known to affect ATPase activity and function of P-gp (Rothnie
et al., 2001). The yeast membrane ergosterol, a substitute of
cholesterol, can also affect the eﬄux functions of Pdr5p (Kaur
and Bachhawat, 1999). Our group has earlier observed that lipid
species such as ergosterol and sphingolipids are crucial for proper
insertion of Cdr1p to PM and substrate eﬄux (Krishnamurthy,
1999; Pasrija et al., 2008). Notwithstanding, several studies
related to Cdr1p/Cd2p and Mdr1p of C. albicans have provided
very useful information related to their structure and function
in a heterologous expression system, even if expression of
heterologous proteins in S. cerevisiae can be associated with
potential artifacts.
This study addressed these concerns by developing an
endogenous overexpression system for C. albicans multidrug
transporter proteins. We took advantage of an AR isolate
containing a TAC1 GOF mutation (Znaidi et al., 2007; Tsao et al.,
2009). This strain possesses intrinsic high expression capacity of
FIGURE 7 | Effect of FK520 on Cdr1p pump activity. DSY4687-5 cells were analyzed by drug-diffusion assays on YEPD agar containing no FLC (left most panel)
or FLC at 1/4 MICFLC (right most panel). Indicated amounts of the inhibitor were spotted on each filter disk. In the middle panel, solvent for FK520 (ethanol) was placed
on the disk as a solvent control.
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FIGURE 8 | The endogenous overexpression system for expression of a MFS superfamily protein. MDR1 with a C-terminal GFP tag was cloned into
pDS1874 and overexpressed in DSY4684, the strain was designated as ANY-MDR1-GFP. (A) Confocal microscopy images of DSY4684, ANY-MDR1-GFP and its
mutant. (B) Immunoblot analyses of their PM fractions (50 µg total protein) with anti-GFP monoclonal antibody. (C) Agar drug-diffusion assays of DSY4684 and
ANY-MDR1-GFP cells. Susceptibility to the following xenobiotics were tested: Fluconazole (FLC; 10 µg), Anisomycin (ANI; 6 µg) and 4-nitroquinoline 1-oxide (NQO; 1
µg). (D) Drug resistance profiles of DSY4684, ANY-MDR1-GFP and its mutant variant determined by serial dilution assays. For serial dilution assays, the following
drugs were used: ANI (4 µg/ml), FLC (4 µg/ml) and NQO (0.25 µg/ml).
transporters. The deletion of major MDR pumps such as CDR1,
CDR2, and MDR1 made this strain amenable to expression of
MDR variants. Stable integration and overexpression of a single
gene copy under the control of aCDR1 native promoter wasmade
available. The expression plasmid integration can be performed
by single site digestion (BglII) to enable integration into the
genomic locus at the CDR1 promoter.
This new endogenous overexpression system was validated by
overexpressing a GFP tagged version of Cdr1p. The time course
of GFP fluorescence in C. albicans cells expressing the fusion
protein revealed that the protein was being properly trafficked
to the cell surface. Our confocal microscopy and immunoblot
analyses results showed that cells which were grown up to 8
hours had almost all their GFP fluorescence within the PM with
only negligible amounts of trapped intracellular fluorescence.
The overexpressed Cdr1p was fully functional since DSY4687-5
(CDR1-GFP) had significantly higher resistance to all the tested
drugs as compared with the susceptible control strain lacking the
known MDR pumps (DSY4684).
To further explore the suitability of the C. albicans
overexpression system, we recreated earlier three well
characterized crucial TMH mutants of Cdr1p in the endogenous
system (Rawal et al., 2013). Our assays showed that two of the
three mutants, L529A and V532A, behaved similarly as was
the case when overexpressed in S. cerevisiae. Interestingly, the
C1294A mutant showed a few contrasting phenotypes. For
instance, even though R6G and NR transport in C1294A cells
was impaired, the cells continued to display resistance to all
the other tested drugs. [3H] FLC accumulation assay further
confirmed that the mutant variant was specifically defective in
R6G and NR transport.
Considering that Cdr1p possesses multiple overlapping mini-
binding sites within the large binding cavity harboring common
as well as specific residues for a particular substrate (Rawal
et al., 2013), it is plausible that mutating C1294 to alanine might
have specifically perturbed R6G and NR binding/transport.
Contradictorily, it was not the case observed when the C1294A
variant was overexpressed in S. cerevisiae as there it was found to
be susceptible to all tested substrates.
The subtle differences in membrane environment between the
two species could be responsible for this differential behavior of
the mutant. Obviously, this aspect requires further investigation.
Nevertheless, our results point toward distinctive behavior
of membrane pump proteins when expressed in different
environments.
The usefulness of this overexpression system for the
identification and characterization of fungal pump inhibitors
was evident from the fact that the calceneurin inhibitor FK520,
which shows fungicidal synergism with azoles in the Cdr1p
overexpressing S. cerevisiae system (Saini et al., 2005; Nim et al.,
2014), also potentiated the growth inhibition of DSY4687-5 cells
in the presence of FLC at much lower its MIC value.
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In order to extend the application of this newly developed
system for the analyses of other classes of multidrug transporters,
we overexpressed a protein belonging to the MFS superfamily.
For this purpose, Mdr1p of C. albicans was integrated in
DSY4684. We also constructed a variant (Mdr1W248A) in the
same background. Our results indicate that a non-ABC transport
protein could also be functionally overexpressed in the PM
of the host DSY4684. Expectedly, the cells overexpressing the
Mdr1W248A variant were susceptible to all tested drugs, which
is consistent with earlier reports where W248 in TMH5 was
identified as a crucial determinant of substrate recognition and
transport in Mdr1p (Pasrija et al., 2007).
In conclusion, our results justifies the suitability and
utility of this newly developed system for overexpression
and functional characterization for a wide set of membrane
proteins of C. albicans. Additionally, the lack of major
endogenous MDR pumps and a TAC1 mediated constitutive
membrane protein overexpression provides a powerful platform
to identify novel substrates and chemosensitizers. The system
can still be optimized with the deletion of other MDR genes
to serve as a valuable tool for studies on fungal MDR
pumps.
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